- PRICING
- LIVE QUOTES
- LEARN
- HELP
EN
1 Momentum Stock with Solid Fundamentals and 2 We Avoid
The stocks featured in this article have all approached their 52-week highs. When these price levels hit, it typically signals strong business execution, positive market sentiment, or significant industry tailwinds.
However, not all companies with momentum are long-term winners, and many investors have lost money by following short-term trends. All that said, here is one stock we think lives up to the hype and two best left ignored.
Two Stocks to Sell:
Sirius XM (SIRI)
One-Month Return: +2.2%
Known for its commercial-free music channels, Sirius XM (NASDAQ:SIRI) is a broadcasting company that provides satellite radio and online radio services across North America.
Why Should You Dump SIRI?
- Sales trends were unexciting over the last five years as its 1% annual growth was below the typical consumer discretionary company
- Free cash flow margin is on track to jump by 1 percentage points next year, meaning the company will have more resources to pursue growth initiatives, repurchase shares, or pay dividends
- Shrinking returns on capital from an already weak position reveal that neither previous nor ongoing investments are yielding the desired results
Sirius XM’s stock price of $29.89 implies a valuation ratio of 9.7x forward P/E. If you’re considering SIRI for your portfolio, see our FREE research report to learn more.
NeoGenomics (NEO)
One-Month Return: -0.6%
Operating a network of CAP-accredited and CLIA-certified laboratories across the United States and United Kingdom, NeoGenomics (NASDAQ:NEO) provides specialized cancer diagnostic testing services, including genetic analysis, molecular testing, and pathology consultation for oncologists and healthcare providers.
Why Are We Wary of NEO?
- Subscale operations are evident in its revenue base of $746 million, meaning it has fewer distribution channels than its larger rivals
- Negative returns on capital show management lost money while trying to expand the business
- High net-debt-to-EBITDA ratio of 6× increases the risk of forced asset sales or dilutive financing if operational performance weakens
NeoGenomics is trading at $14.17 per share, or 60.2x forward P/E. Dive into our free research report to see why there are better opportunities than NEO.
One Stock to Watch:
Texas Roadhouse (TXRH)
One-Month Return: -0.8%
With locations often featuring Western-inspired decor, Texas Roadhouse (NASDAQ:TXRH) is an American restaurant chain specializing in Southern-style cuisine and steaks.
Why Do We Watch TXRH?
- Rapid rollout of new restaurants to capitalize on market opportunities makes sense given its strong same-store sales performance
- Same-store sales growth over the past two years shows it’s successfully drawing diners into its restaurants
- Stellar returns on capital showcase management’s ability to surface highly profitable business ventures
At $192.29 per share, Texas Roadhouse trades at 28.9x forward P/E. Is now the time to initiate a position? Find out in our full research report, it’s free.
Stocks We Like Even More
WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don’t just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.
But our AI platform says the party isn’t over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.